Peer-reviewed study demonstrates LEON’s FR-JET® modular mixer enables stable high-concentration mRNA-LNPs with enhanced in vivo activity
Planegg/Munich (Germany), January 9th, 2026 – A new study published in Pharmaceutics shows that LEON’s FR-JET® modular mixer addresses key manufacturing challenges by enabling the production of highly concentrated lipid nanoparticles (LNPs). The study demonstrates that LNP formulation at significantly higher lipid mixture concentrations, beyond those currently reported in the literature and industry sources, can improve biological […]
leon-nanodrugs appoints Dr. Wolfgang Hofmann as Chief Executive Officer
Munich, Planegg (Germany), June 4, 2025 – We are pleased to announce the appointment of Dr. Wolfgang Hofmann as its new Chief Executive Officer (CEO). With his extensive experience in scaling life science ventures and leading international teams, Dr. Hofmann will guide LEON through its next phase of growth. Under his leadership, LEON will focus […]
Enhancing Small Molecule Solubility: Advancing Liposomal Drug Delivery with FR-JET®
We’re excited to share a case study on our successful collaboration with Glatt, highlighting how our FR-JET® technology enables superior liposomal formulation. Key insights from our feasibility study: Successfully formulated naproxen-loaded liposomes using various lipid compositions, highlighting new drug delivery possibilities. Achieved liposome sizes ≤150 nm and a PDI of ≤0.14, demonstrating robust and efficient formulation screening. […]
Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery
We are pleased to announce the successful conclusion of an independent feasibility study with Evonik Canada Inc., part of Evonik Industries, one of the world´s leading specialty chemicals companies. The study aimed to evaluate the capabilities of LEON’s proprietary FR-JET technology and confirmed its exceptional performance in manufacturing nanoparticles for drug delivery. READ MORE […]
leon-nanodrugs secures funds in a series D financing
LEON announced today the closing of a Series D financing round. New lead investor LBBW Venture Capital closed the round together with new investors and existing shareholders like Albany Private Equity Holdings Pty Ltd., CD-Venture GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Partners, TVM Life Science Innovation I L.P., and others. READ MORE
Technical Evaluation by CMAC
In a significant stride towards advancing nanoparticle drug delivery manufacturing technology, LEON proudly announces a pioneering technical evaluation by CMAC, University of Strathclyde. This joint effort brings together the expertise of Professor Yvonne Perrie and the team at CMAC with LEON’s science experts. The aim of the studies was to test LEON’s proprietary state-of-the-art FR-JET […]
NANOme® has been honored with the prestigious iF Design Award 2024
Our NANOme® device has been honored with the prestigious iF Design Award! This award is a great recognition, not only of LEON´s innovative design, but also signifies our commitment to delivering high quality leading edge solutions to the pharmaceutical manufacturing sector. READ MORE: NANOme wins iF design award
LEON sets up lab facilities at the Innovation and Start-Up Center for Biotechnology (IZB) in Munich
leon-nanodrugs GmbH, announced today the establishment of their own lab facilities at the Start-Up Center for Biotechnology (IZB) in Munich. The new R&D capacities set the stage for completion of product development for LEON’s manufacturing devices and will afterwards be used to showcase the devices and provide process development services to clients using LEON’s equipment. […]
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
[vc_row][vc_column][vc_column_text]LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer, from development stage to commercial scale. The prerequisites to manufacture the LEON reactor in series are therefore met – a milestone achievement on the road to broad application of the NANOnow […]
Interview: Unleashing the power of LNP encapsulation
Very interesting interview with our CFO, Christian Nafe in the latest winter edition of European Biotechnology Magazine. READ MORE